NEW YORK–(BUSINESS WIRE) June 20, 2023 — Pfizer (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi…Original Article
Pfizer’s Talzenna (talazoparib) in Combination with Xtandi (enzalutamide) Receives U.S. FDA Approval for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
